StreetInsider.com News Articles

Form 6-K SciSparc Ltd. For: Oct 26

Mon, 26 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261026/27233893.html

Form 6-K SciSparc Ltd. For: Oct 23

Fri, 23 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261023/27224847.html

NeuroThera Labs completes manufacturing milestone for Tourette trial

Thu, 22 Oct 2026 08:59:26 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) has completed manufacturing of its investigational drug candidate SCI-110 and obtained batch release certification from a European Qualified Person, clearing the way for shipment of clinical trial materials to study sites.

The certification is a regulatory step that authorizes the distribution of clinical supply for NeuroThera's FDA-approved Phase IIb clinical trial evaluating SCI-110 for the treatment of Tourette syndrome in adults. The company said all three participating clinical sites have completed initiation activities and are prepared to receive drug supplies, with shipments expected in the near term.

The trial

NeuroThera Labs completes manufacturing milestone for Tourette trial

Thu, 22 Oct 2026 08:59:26 -0400

The trial

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Thu, 22 Oct 2026 08:55:00 -0400

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has achieved further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults.

NeuroThera has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Thu, 22 Oct 2026 08:55:00 -0400

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Thu, 22 Oct 2026 08:55:00 -0400

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Thu, 22 Oct 2026 08:55:00 -0400

SciSparc shifts strategy toward agentic AI in cybersecurity and finance

Mon, 19 Oct 2026 08:35:24 -0400

SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company based in Tel Aviv, Israel, announced it will shift its strategic focus toward agentic AI-powered technologies, with an emphasis on cybersecurity and finance applications.

The announcement, made Oct. 19, 2026, follows a series of related moves by the company, including a decision on July 27, 2026, to target the agentic AI market and the establishment of a Scientific Advisory Board for AI and Cybersecurity on Aug. 26, 2026.

The company said it intends to evaluate technologies, companies, and business opportunities across the agentic AI ecosystem. Agentic AI refers to artificial intelligence systems designed to

SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications

Mon, 19 Oct 2026 08:35:00 -0400

TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.

Building on its previously announcements from October 15, decision on July 27, 2026 to target the Agentic AI market and the announcement on August 26, 2026 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the Company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and

SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications

Mon, 19 Oct 2026 08:35:00 -0400

Form 6-K SciSparc Ltd. For: Oct 15

Thu, 15 Oct 2026 13:31:00 -0400

si-local-file:///var/storage/secattach/20261015/27192584.html

Form 6-K SciSparc Ltd. For: Oct 15

Thu, 15 Oct 2026 11:47:00 -0400

si-local-file:///var/storage/secattach/20261015/27192110.html

SciSparc shifts focus to agentic AI, cybersecurity, and finance tech

Thu, 15 Oct 2026 07:06:50 -0400

SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company based in Tel Aviv, Israel, announced plans to shift its strategic focus toward agentic AI-powered technologies, with an emphasis on cybersecurity and finance technology applications.

The announcement, made Oct. 15, 2026, builds on two earlier decisions: a July 27, 2026 move to target the agentic AI market and an Aug. 26, 2026 establishment of a Scientific Advisory Board for AI and Cybersecurity.

The company said it intends to evaluate technologies, companies, and business opportunities across the agentic AI ecosystem. Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

Thu, 15 Oct 2026 07:06:00 -0400

TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.

Building on its previously announced decision on July 27, 2026 to target the Agentic AI market and the announcement on August 26, 2026 of the establishment of its Scientific Advisory Board for AI and Cybersecurity, the Company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, with a focus on applications such as in cybersecurity and finance technologies.

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

Thu, 15 Oct 2026 07:06:00 -0400

Form 6-K SciSparc Ltd. For: Oct 07

Wed, 07 Oct 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20261007/27158877.html

SciSparc unit reports GPU speedup in gene combination analysis

Wed, 07 Oct 2026 08:22:40 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced that CliniQuantum Ltd., a majority-owned subsidiary of NeuroThera Labs Inc. (TSXV: NTLX), reported results from a computational benchmark of its GPU-accelerated quantum-simulation platform, according to a press release.

The platform achieved approximately 16.8 times faster processing using a single NVIDIA T4 Tensor Core GPU alongside a 64-core CPU machine, compared with the same machine running only on CPU. The benchmark was conducted on an AWS g4dn.16xlarge EC2 instance using IBM Qiskit Aer GPU-based quantum simulation.

The test used a clinical gene-expression dataset from 11 patients containing 3,531 gene-expression features. The algorithm searched for correlated three-gene configurations across

SciSparc unit reports GPU speedup in gene combination analysis

Wed, 07 Oct 2026 08:22:40 -0400

The test used a clinical gene-expression dataset from 11 patients containing 3,531 gene-expression features. The algorithm searched for correlated three-gene configurations across

SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum A